Burcu Eryilmaz

Learning Stage

BURCU ERYILMAZ was appointed as the global franchise head, rare diseases at Sanofi in 2023. In this capacity, she serves as a member of the Sanofi Specialty Care Executive Team with responsibility for the company’s rare disease therapies globally. Prior to this role, Eryilmaz was the global head, rare nephrology and venglust at for almost three years focusing on Sanofi’s Fabry portfolio with Fabrazyme® and venglustat–a small molecule currently in development for Gaucher Disease Type 3, GM2 and Fabry Disease. Eryilmaz joined Sanofi in 2018 as head, US business operations and led critical business functions such as forecasting & analytics, market research, commercial training, commercial operations, Launch Excellence, Data Management and Data Privacy that support six business units representing 15 disease states and 20 products. Eryilmaz has an MBA from Carnegie Mellon University Tepper School of Business and a BS in industrial engineering from Bilkent University in Ankara, Turkey.